Company Overview of Warner-Lambert Company LLC
Warner-Lambert Company LLC manufactures and markets pharmaceutical, consumer health care, and confectionery products. It offers pharmaceuticals drugs, over-the-counter health care products, shaving and pet care products, chewing gums, breath-mints, and cough/throat tablets. The company was founded in 1920 and is based in Morris Plains, New Jersey. Warner-Lambert Company LLC operates as a subsidiary of Pfizer Inc.
201 Tabor Road
Morris Plains, NJ 07950
Founded in 1920
Key Executives for Warner-Lambert Company LLC
Senior Vice President and General Counsel
Senior Vice President of Public Affairs
Senior Vice President of Human Resources
Compensation as of Fiscal Year 2015.
Warner-Lambert Company LLC Key Developments
Kaplan Fox & Kilsheimer LLP Announces $190 Million Settlement with Pfizer, Inc. and Warner-Lambert Co
Apr 21 14
Kaplan Fox & Kilsheimer LLP announced a $190 Million settlement, subject to court approval, with Pfizer Inc. and Warner-Lambert Co. in re Neurontin Antitrust Litigation, No. 02-1390, pending in the District of New Jersey. Kaplan Fox serves as one of two co-lead counsel representing a class of direct purchasers of Neurontin from Pfizer Inc. and Warner-Lambert Co. between December 11, 2002 and August 31, 2008 and who purchased generic Gabapentin, alleging that Pfizer Inc. and Warner-Lambert Co. delayed the market entry of generic competitors, forcing class members to pay artificially inflated prices for Neurontin and its generic equivalents, by among other things, repeated filing of sham patent suits and illegal off-label promotion.
RICO Claim Against Pfizer Inc., Warner-Lambert Company LLC Alleges Fraudulent Off-Label Marketing May Proceed
Dec 13 13
The U.S. Supreme Court declined to review a First U.S. Circuit Court of Appeals' decision reversing summary judgment in favor of a pharmaceutical firm in a civil Racketeer Influenced and Corrupt Organizations Act action brought by a third-party payor arising from the defendant's alleged fraudulent off-label marketing campaign. A class of third-party payors alleged Pfizer Inc. and Warner Lambert Co. engaged in a fraudulent off-label marketing campaign that caused third-party payors to pay for Neurontin prescriptions that were ineffective for the off-label conditions at issue, and that the plaintiffs suffered injuries in paying for those prescriptions. A district court granted summary judgment in favor of the defendants after concluding the plaintiffs failed to raise a fact issue as to causation. The plaintiffs appealed. The First Circuit reversed the district court's judgment. The First Circuit held the plaintiffs presented adequate evidence that Pfizer fraudulently promoted Neurontin for off-label treatment of bipolar disorder, such conduct likely caused harm to the plaintiffs and that such harm would be the expected consequence of Pfizer's conduct. The First Circuit held the causal chain between Pfizer's conduct and the plaintiffs' injuries was sufficiently direct to survive a summary judgment motion. Under U.S. Supreme Court precedent, the plaintiffs were not required to demonstrate they directly relied on Pfizer's misrepresentations, but instead needed to show only some direct relation between the injury asserted and the injurious conduct alleged. Therefore, the First Circuit remanded the case for further proceedings.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries